C C Earle

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Follow-up of patients with curatively resected colorectal cancer: a practice guideline
    Alvaro Figueredo
    Hamilton Regional Cancer Centre McMaster University, Hamilton, Ontario, Canada
    BMC Cancer 3:26. 2003
  2. ncbi Identifying potential indicators of the quality of end-of-life cancer care from administrative data
    Craig C Earle
    Division of Population Sciences Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:1133-8. 2003
  3. ncbi Failing to plan is planning to fail: improving the quality of care with survivorship care plans
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:5112-6. 2006
  4. ncbi Cancer physicians' attitudes toward colorectal cancer follow-up
    C C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 14:400-5. 2003
  5. ncbi Influenza vaccination in elderly patients with advanced colorectal cancer
    Craig C Earle
    Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:1161-6. 2003
  6. ncbi Quality of non-breast cancer health maintenance among elderly breast cancer survivors
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, Boston 02115, USA
    J Clin Oncol 21:1447-51. 2003
  7. ncbi Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness
    Monika K Krzyzanowska
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney St, 454 STE 21 24, Boston, MA 02115, USA
    J Clin Oncol 21:3409-14. 2003
  8. ncbi Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients
    Craig C Earle
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 98:172-80. 2006
  9. ncbi Evaluating claims-based indicators of the intensity of end-of-life cancer care
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Qual Health Care 17:505-9. 2005
  10. ncbi Trends in the aggressiveness of cancer care near the end of life
    Craig C Earle
    MSc, Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, 454 STE 21 24, Boston, MA 02115, USA
    J Clin Oncol 22:315-21. 2004

Collaborators

Detail Information

Publications74

  1. pmc Follow-up of patients with curatively resected colorectal cancer: a practice guideline
    Alvaro Figueredo
    Hamilton Regional Cancer Centre McMaster University, Hamilton, Ontario, Canada
    BMC Cancer 3:26. 2003
    ..A systematic review was conducted to evaluate the literature regarding the impact of follow-up on colorectal cancer patient survival and, in a second phase, recommendations were developed...
  2. ncbi Identifying potential indicators of the quality of end-of-life cancer care from administrative data
    Craig C Earle
    Division of Population Sciences Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:1133-8. 2003
    ..To explore potential indicators of the quality of end-of-life services for cancer patients that could be monitored using existing administrative data...
  3. ncbi Failing to plan is planning to fail: improving the quality of care with survivorship care plans
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:5112-6. 2006
    ..This article reviews the elements of the proposed survivorship care plan and discusses areas of research and development needed to make them part of standard oncology practice...
  4. ncbi Cancer physicians' attitudes toward colorectal cancer follow-up
    C C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 14:400-5. 2003
    ..The optimal follow-up strategy for colorectal cancer is unknown...
  5. ncbi Influenza vaccination in elderly patients with advanced colorectal cancer
    Craig C Earle
    Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:1161-6. 2003
    ..To examine influenza vaccination use in patients undergoing chemotherapy for advanced cancer...
  6. ncbi Quality of non-breast cancer health maintenance among elderly breast cancer survivors
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, Boston 02115, USA
    J Clin Oncol 21:1447-51. 2003
    ..To assess the quality of preventive health care, the role of health care participation, and the patient and provider characteristics associated with high-quality care for breast cancer survivors...
  7. ncbi Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness
    Monika K Krzyzanowska
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney St, 454 STE 21 24, Boston, MA 02115, USA
    J Clin Oncol 21:3409-14. 2003
    ..To evaluate the use and effectiveness of cancer-directed therapy in elderly patients with locally advanced pancreatic cancer (LAPC)...
  8. ncbi Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients
    Craig C Earle
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 98:172-80. 2006
    ..e., better outcomes). We examined associations between physician specialty and outcomes in a population-based cohort of elderly ovarian cancer surgery patients...
  9. ncbi Evaluating claims-based indicators of the intensity of end-of-life cancer care
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Qual Health Care 17:505-9. 2005
    ..To evaluate measures that could use existing administrative data to assess the intensity of end-of-life cancer care...
  10. ncbi Trends in the aggressiveness of cancer care near the end of life
    Craig C Earle
    MSc, Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, 454 STE 21 24, Boston, MA 02115, USA
    J Clin Oncol 22:315-21. 2004
    ..To characterize the aggressiveness of end-of-life cancer treatment for older adults on Medicare, and its relationship to the availability of healthcare resources...
  11. ncbi Two schedules of second-line irinotecan for metastatic colon carcinoma
    Craig C Earle
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 101:2533-9. 2004
    ....
  12. ncbi Identifying cancer relapse using SEER-Medicare data
    Craig C Earle
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Med Care 40:IV-75-81. 2002
    ..Linking administrative data to registry data, as in the creation of the SEER (Surveillance, Epidemiology, and End Results) and Medicare data set, can provide the ability to infer the occurrence of relapse in selected situations...
  13. doi Long term care planning for cancer survivors: a health services research agenda
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, SM 271, Boston, MA 02115, USA
    J Cancer Surviv 1:64-74. 2007
    ..The IOM stated that survivorship care plans 'have strong face validity and can reasonably be assumed to improve care unless and until evidence accumulates to the contrary.'..
  14. ncbi Under use of necessary care among cancer survivors
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 101:1712-9. 2004
    ..Special attention and education are needed to ensure that survivors receive optimal medical services...
  15. ncbi Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis
    C C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1064-70. 2001
    ..To compare the effectiveness of chemotherapy given to elderly patients in routine practice for stage IV non-small-cell lung cancer (NSCLC) with the efficacy observed in randomized trials...
  16. ncbi Who gets chemotherapy for metastatic lung cancer?
    C C Earle
    Center for Outcomes and Policy Research, Department of Adult Oncology Dana Farber Cancer Institute, Boston, MA 02115, USA
    Chest 117:1239-46. 2000
    ..To determine the prevalence and factors associated with chemotherapy use in elderly patients presenting with advanced lung cancer...
  17. ncbi Systematic overview of cost-utility assessments in oncology
    C C Earle
    Center for Outcomes and Policy Research, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 18:3302-17. 2000
    ..We critically reviewed the CUA literature and its role in informing clinical oncology practice, research priorities, and policy...
  18. ncbi Impact of referral patterns on the use of chemotherapy for lung cancer
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, Boston, MA 02115, USA
    J Clin Oncol 20:1786-92. 2002
    ..To determine the extent to which unexplained variation in the use of chemotherapy for advanced lung cancer is due to access to oncologists' services as opposed to treatment decisions made after seeing an oncologist...
  19. ncbi An assessment of methods to combine published survival curves
    C C Earle
    University of Ottawa and Ottawa Regional Cancer Centre, Ontario, Canada
    Med Decis Making 20:104-11. 2000
    ..To assess the accuracies of different techniques for combining published survival curves, for use in disease modeling applications...
  20. ncbi Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials
    C C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Eur J Cancer 35:1059-64. 1999
    ..The aim of this study was to assess whether adjuvant chemotherapy after curative resection of gastric cancer increases survival rates...
  21. doi Mental health service utilization among long-term cancer survivors
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Cancer Surviv 1:156-60. 2007
    ..Although generally well-adjusted, a subset of cancer survivors have been observed to experience ongoing psychological distress. There has been little study of mental health care utilization among cancer survivors, however...
  22. ncbi Outcomes research in oncology: history, conceptual framework, and trends in the literature
    S J Lee
    Center for Outcomes and Policy Research, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 92:195-204. 2000
    ..We suggest that as different branches of investigation develop their own literature and methodology-in effect, outgrowing the generic label of outcomes research-they become identified by separate, more precise terms...
  23. ncbi Cost of combined modality interventions for stage III non-small-cell lung cancer
    W K Evans
    University of Ottawa, Ontario, Canada
    J Clin Oncol 15:3038-48. 1997
    ..To evaluate the cost-effectiveness (CE) of new combined modality strategies in patients with stage III non-small-cell lung cancer (NSCLC)...
  24. ncbi Thymidylate synthase expression in stage II and III colon cancer: a retrospective review
    A Tomiak
    London Regional Cancer Centre, London, Ontario, Canada
    Am J Clin Oncol 24:597-602. 2001
    ..The lack of difference in outcome for patients with low and high TS receiving chemotherapy suggests that high TS levels may predict greater benefit from adjuvant treatment...
  25. doi Marital status and survival following bladder cancer
    G Dabral Datta
    Harvard School of Public Health, Department of Society, Human Development and Health, 677 Huntington Ave, Kresge Building 7 Floor, Boston, MA 02115, USA
    J Epidemiol Community Health 63:807-13. 2009
    ..Marital status has been implicated as a prognostic factor in bladder cancer survival. However, few studies have explored potential mechanisms through which this might occur...
  26. doi Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer
    C C Earle
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Surg Oncol 100:525-8. 2009
    ..Failing to meet the benchmark of 12 lymph nodes in resection specimens is an indication for adjuvant chemotherapy in stage II colon cancer...
  27. pmc Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
    P C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 20:475-80. 2009
    ..Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer...
  28. ncbi Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer
    J A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 18:1185-9. 2007
    ..Targeting the epidermal growth factor receptor and angiogenesis have proven useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of both pathways is unknown...
  29. doi Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data
    Michael E Stokes
    i3 Innovus, Medford, MA, USA
    Value Health 11:213-20. 2008
    ..Assessing the value of these treatments is compromised by a paucity of data on the impact of recurrence on economic costs and survival. The purpose of this study was to shed light on these issues...
  30. pmc Trends in follow-up and preventive care for colorectal cancer survivors
    Claire F Snyder
    Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    J Gen Intern Med 23:254-9. 2008
    ..As cancer patients transition from treatment to survivorship, the responsibility of primary care providers (PCPs) versus oncology specialists is unclear...
  31. ncbi Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer
    James A Hayman
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 69:1001-7. 2007
    ..The objective of this study was to examine the utilization patterns of palliative RT among elderly patients with Stage IV NSCLC and, in particular, to identify factors associated with its use...
  32. ncbi Cancer survivorship research and guidelines: maybe the cart should be beside the horse
    Craig C Earle
    J Clin Oncol 25:3800-1. 2007
  33. ncbi Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
    ....
  34. ncbi Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients
    Ewout W Steyerberg
    Center for Medical Decision Making, Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    J Clin Oncol 25:2389-96. 2007
    ..Referring physicians and treating specialists must ensure that elderly patients are not deprived of the opportunity to consider all of their treatment options...
  35. ncbi Methodological issues in the use of administrative claims data to study surveillance after cancer treatment
    Ann Butler Nattinger
    Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Med Care 40:IV-69-74. 2002
    ..Administrative claims databases linked to tumor registry data provide an excellent opportunity for studying the follow-up care of cancer patients...
  36. pmc Lower use of hospice by cancer patients who live in minority versus white areas
    Jennifer S Haas
    Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120 1613, USA
    J Gen Intern Med 22:396-9. 2007
    ..Although hospice care can alleviate suffering at the end of life for patients with cancer, it remains underutilized, particularly by African Americans and Hispanics...
  37. ncbi Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  38. ncbi Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer
    Monika K Krzyzanowska
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 67:211-8. 2007
    ..Economic modeling can be used to explore the potential of such novel therapies and to inform clinical trial design...
  39. ncbi Preventive care for colorectal cancer survivors: a 5-year longitudinal study
    Claire F Snyder
    Division of General Internal Medicine, Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    J Clin Oncol 26:1073-9. 2008
    ..To explore the mix of physician specialties that long-term survivors visit and how the mix relates to preventive care...
  40. pmc Racial segregation and disparities in cancer stage for seniors
    Jennifer S Haas
    Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Gen Intern Med 23:699-705. 2008
    ..Disparities in cancer survival may be related to differences in stage. Segregation may be associated with disparities in stage, particularly for cancers for which screening promotes survival...
  41. pmc Toward population-based indicators of quality end-of-life care: testing stakeholder agreement
    Eva Grunfeld
    Cancer Outcomes Research Program, Cancer Care Nova Scotia, Halifax, Nova Scotia
    Cancer 112:2301-8. 2008
    ..The objective of this study was to assess stakeholder acceptability of QIs of end-of-life (EOL) care that potentially were measurable from population-based administrative health databases...
  42. ncbi A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma
    David P Ryan
    Gastrointestinal Cancer Center, Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
    Cancer 94:97-103. 2002
    ..Chemotherapy with gemcitabine is the standard first-line treatment. In a Phase II trial at one academic cancer center, the clinical safety and activity of combining gemcitabine and docetaxel were assessed...
  43. ncbi A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
    Charles S Fuchs
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 94:3186-91. 2002
    ..A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerability of the drug in a population of U.S. patients...
  44. pmc Racial segregation and disparities in breast cancer care and mortality
    Jennifer S Haas
    Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02120 1613, USA
    Cancer 113:2166-72. 2008
    ..Questions have existed as to whether residential segregation is a mediator of racial/ethnic disparities in breast cancer care and breast cancer mortality, or has a differential effect by race/ethnicity...
  45. pmc Racial composition of hospitals: effects on surgery for early-stage non-small-cell lung cancer
    Christopher S Lathan
    Department of Medical Oncology, Division of Population Sciences, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:4347-52. 2008
    ..Our study examines the relationship between the percentage of black patients treated at a hospital to determine whether it affects the likelihood of obtaining cancer-directed surgery for patients with non-small-cell lung cancer (NSCLC)...
  46. pmc Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?
    Craig C Earle
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 26:3860-6. 2008
    ..Whether the concept of overly aggressive treatment represents a quality-of-care issue that is acceptable to all involved stakeholders is an open question...
  47. ncbi The outcomes and costs of acute myeloid leukemia among the elderly
    Joseph Menzin
    Boston Health Economics, Inc, 20 Fox Rd, Waltham, MA 02451, USA
    Arch Intern Med 162:1597-603. 2002
    ..The incidence of acute myeloid leukemia (AML) among the elderly can be expected to grow as the population continues to age. However, data on current treatment practices and costs for this form of cancer are sparse...
  48. ncbi Measuring complications of cancer treatment using the SEER-Medicare data
    Arnold L Potosky
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
    Med Care 40:IV-62-8. 2002
    ..One category of outcomes amenable to research using Medicare claims is complications of cancer treatments: the unintentional, adverse side effects or sequelae of interventions used to treat or palliate cancer patients...
  49. doi Delays in referral and diagnosis for chronic hematologic malignancies: a literature review
    Gregory A Abel
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 49:1352-9. 2008
    ..Unfortunately, the outcomes associated with such delays are largely unreported, possibly because delay is complex to define and difficult to measure...
  50. ncbi Looking back from death: the value of retrospective studies of end-of-life care
    Craig C Earle
    J Clin Oncol 24:838-40. 2006
  51. pmc Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology
    Eva Grunfeld
    Cancer Outcomes Research Program, Cancer Care Nova Scotia, Dalhousie University, Halifax, Canada
    Palliat Med 20:769-77. 2006
    ..Using administrative data is an efficient, population-based method to monitor quality of care which can compliment other methods, such as qualitative and purposefully collected clinical data...
  52. pmc Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients
    Jonathan E Lim
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Ann Surg 237:74-85. 2003
    ..To analyze prognostic factors influencing pancreatic cancer survival following curative resection, using prospectively collected, population-based data...
  53. pmc Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline
    Craig C Earle
    Dana Farber Cancer Institute, Boston, Mass, USA
    Can J Surg 45:438-46. 2002
    ..To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer (T1-4, N1-2, M0)...
  54. ncbi The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer
    A David McCollum
    Texas Oncology, PA, and Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Am J Clin Oncol 29:40-4. 2006
    ..We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomide (Cape/Thal) in patients with refractory metastatic CRC...
  55. ncbi A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    David P Ryan
    Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Invest 21:505-11. 2003
    ....
  56. ncbi A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Dig Dis Sci 50:2218-23. 2005
    ..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population...
  57. ncbi The effect of race on invasive staging and surgery in non-small-cell lung cancer
    Christopher S Lathan
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:413-8. 2006
    ..To isolate the effect of decision making from access to care, we used receipt of surgical staging as a proxy for access and willingness to undergo invasive procedures, and examined treatments and outcomes by race...
  58. ncbi Trends in the treatment of acute myeloid leukaemia in the elderly
    Kathleen Lang
    Boston Health Economics, Inc, Waltham, Massachusetts 02451, USA
    Drugs Aging 22:943-55. 2005
    ..This study documents changes in treatment patterns and outcomes among elderly AML patients over the past decade...
  59. ncbi Patterns of care studies: creating "an environment of watchful concern"
    Craig C Earle
    J Clin Oncol 21:4479-80. 2003
  60. ncbi Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients
    Ewout W Steyerberg
    Department of Public Health, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    J Clin Oncol 23:510-7. 2005
    ..We investigated racial disparities in access to surgical evaluation, receipt of surgery, and survival among elderly patients with locoregional esophageal cancer...
  61. pmc Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers
    Eva Grunfeld
    Ottawa Regional Cancer Centre and Division of Medical Oncology, University of Ottawa, and Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa Hospital, ON
    CMAJ 170:1795-801. 2004
    ..We prospectively examined the psychosocial, occupational and economic impact of caring for a person with a terminal illness...
  62. ncbi Does reimbursement influence chemotherapy treatment for cancer patients?
    Mireille Jacobson
    University of Michigan, Ann Arbor, USA
    Health Aff (Millwood) 25:437-43. 2006
    ..Providers who were more generously reimbursed, however, prescribed more-costly chemotherapy regimens to metastatic breast, colorectal, and lung cancer patients...
  63. ncbi Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  64. ncbi Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  65. ncbi Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....
  66. pmc Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)
    Elizabeth B Lamont
    Massachusetts General Hospital Cancer Center and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 98:1335-8. 2006
    ....
  67. ncbi Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score
    Ewout W Steyerberg
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 24:4277-84. 2006
    ..We aimed to develop and validate a simple risk score for surgical mortality that could be applied to administrative data...
  68. ncbi Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer
    Michael J Hassett
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, 454 STE 21, Boston, MA 02115 6084, USA
    J Natl Cancer Inst 98:1108-17. 2006
    ..The number, nature, and costs of serious adverse effects experienced by younger women receiving chemotherapy for breast cancer outside of clinical trials are unknown...
  69. ncbi A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
    ..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors...
  70. ncbi Radiation therapy after mastectomy between 1991 and 1999 in elderly women: response to clinical trial information
    Rinaa S Punglia
    Department of Radiation Oncology and Center for Outcomes and Policy Research, Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3474-82. 2006
    ..We sought to study the receipt of PMRT in elderly women in this period, using a population-based cohort of women with breast cancer...
  71. ncbi Do unto others
    Craig C Earle
    J Clin Oncol 24:3331-2. 2006
  72. ncbi Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women
    Rinaa S Punglia
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 66:56-63. 2006
    ..We sought to study the effect of distance to the nearest radiation treatment facility on the use of postmastectomy radiation therapy (PMRT) in elderly women...
  73. ncbi Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..We studied the efficacy of cetuximab therapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oral inhibitor of the tyrosine kinase domain of the epidermal growth factor receptor...
  74. ncbi Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis
    Joseph Menzin
    Boston Health Economics, Inc, Waltham, Massachusetts, USA
    Drugs Aging 21:737-46. 2004
    ..To fill this void, our study uses population-based data to evaluate longer-term treatment patterns, outcomes and costs among elderly Medicare beneficiaries following their diagnosis of CML...